Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Objective: To evaluate the pharmacogenetic relationship between CFH haplotypes and single nucleotide polymorphisms (SNPs) with response to ranibizumab treatment for neovascular age-related macular degeneration (nAMD). Patients and Methods: This was a prospective cohort study involving 70 treatment-naive nAMD patients. Patients were genotyped for CFH haplotypes and SNPs in the C3, ARMS2, and mtDNA genes. Visual acuity and central macular thickness were assessed at baseline and during 6 monthly follow-up visits. Multivariate logistic regression was used to determine the association between genotypes and a gain of ≥15 letters at the 6-month endpoint after adjusting for potential confounders. Results:CFH haplotypes were associated with a gain of ≥15 letters at the 6-month endpoint (p = 0.046). Patients expressing protective haplotypes were more likely to achieve a gain of ≥15 letters relative to the greatly increased risk haplotypes [OR 6.58 (95% CI: 1.37, 31.59)]. Conclusion:CFH is implicated in nAMD patient treatment response to ranibizumab.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is substantial interpatient variability in the treatment response, and individual patients appear to respond better to different anti-VEGF agents, which suggests a pharmacogenetic effect [31,32].”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [31]
In the citing paper
“There is substantial interpatient variability in the treatment response, and individual patients appear to respond better to different anti-VEGF agents, which suggests a pharmacogenetic effect [31,32].”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [31]
In the citing paper
“There is substantial interpatient variability in the treatment response, and individual patients appear to respond better to different anti-VEGF agents, which suggests a pharmacogenetic effect [31,32].”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [31]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 23 · Cited by 10
Metadata
- Authors
- Chaudhary, V., Brent, M., Lam, W.-C., Devenyi, R., Teichman, J., Mak, M., Barbosa, J., Kaur, H., Carter, R., & Farrokhyar, F.
- Affiliations
- St. Joseph’s Healthcare Hamilton (CA)
- University of Toronto (CA)
- McMaster University (CA)
- ORCID
- Venue
- Ophthalmologica
- Publisher
- S. Karger AG
- Published
- 2016
- Volume
- 236
- Issue
- 2
- Pages
- 88-94
- ISSN
- 0030-3755 (ISSN-L)
- 1423-0267
- OpenAlex
- W2469056629
- Cited by
- 10
- References
- 23
- Citations by year
- 2024: 3 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 2
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Ophthalmologica (publishedVersion)
- PubMed (publishedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- neovascular age-related macular degeneration, ranibizumab, treatment response, complement factor H, single nucleotide polymorphisms, pharmacogenetics, C3 gene, mitochondrial DNA, visual acuity, central macular thickness
- MeSH terms
- Ranibizumab, Aged, 80 and over, DNA, Female, Fluorescein Angiography, Follow-Up Studies, Fundus Oculi, Gene Frequency, Genotype, Humans, Male, Prospective Studies, Risk Factors, Time Factors, Genetic Predisposition to Disease, Angiogenesis Inhibitors, Polymorphism, Single Nucleotide, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response. https://app.cochat.ai/papers/10.1159/000446819
- The paper
- Chaudhary, V., Brent, M., Lam, W.-C., Devenyi, R., Teichman, J., Mak, M., Barbosa, J., Kaur, H., Carter, R., & Farrokhyar, F. (2016). Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response. Ophthalmologica. https://doi.org/10.1159/000446819
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.